ArticleClinical and translational gastroenterology2026
Mesenteric Adipose Tissue Volume Predicts Response to Antitumor Necrosis Factor Therapy in Biological-Naïve Patients With Crohn's Disease.
Article in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionCrohn's disease is associated with varying degrees of mesenteric adipose tissue (MAT) hypertrophy. The study aimed to evaluate whether MAT hypertrophy, measured by MAT volume, is associated with worse response to anti-tumor necrosis factor alpha (TNF-α) therapy in biologic-naïve patients with Crohn's disease (CD).
methodsA cohort of consecutive patients with CD who underwent computed tomography or MRI before the start of the anti-TNF-α therapy was included. Total MAT volume, excluding large vessels, was estimated. Primary outcomes-dose intensification, surgery, and withdrawal of anti-TNF-α therapy-were evaluated at 3 and 12 months after the initiation of treatment. We performed a multivariate logistic regression model to identify MAT volume as an independent risk factor of poor response to anti-TNF-α.
resultsFifty biologic-naïve, consecutive patients with CD were included. The median MAT volume was 559.5 cm 3 (IQR: 410.3-891.9). MAT volume was positively correlated with weight (ρ = 0.66, P < 0.001) and age (ρ = 0.5, P < 0.001). Multivariate regression model showed that higher MAT volume independently predicted a poor response to anti-TNF-α treatment, as indicated by a greater need for dose intensification of anti-TNF-α agents within 12 months (adjusted odds ratio [OR a ]: 1.36; 95% CI: 1.08-1.81; P = 0.016) and an increased risk of CD surgery within 3 months (OR a : 1.65; 95% CI: 1.08-3.05; P = 0.048). DISCUSSION: MAT volume predicted an increased need for anti-TNF-α dose intensification and surgery in patients with biological-naïve Crohn's disease. MAT volume could be a valuable measure for identifying patients at risk of a poor anti-TNF-α response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.